Dextrose Monohydrate 50% Injection shortage
Current 4 presentations · 2 manufacturers · first FDA posting 2022-01-13 · last update 2026-10-08
Manufacturers: Amphastar Pharmaceuticals, Inc., Hospira, Inc., a Pfizer Company
Stated reasons (per FDA): Demand increase for the drug; Other
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1) | Amphastar Pharmaceuticals, Inc. | Current Limited Availability |
Demand increase for the drug | Estimated recovery: TBD | Posted 01/13/2022 Updated 10/05/2026 |
| Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02) | Hospira, Inc., a Pfizer Company | Current Limited Availability |
Other | Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Posted 01/13/2022 Updated 10/08/2026 |
| Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16) | Hospira, Inc., a Pfizer Company | Current Unavailable |
Other | Next Delivery: October 2026; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay | Posted 01/13/2022 Updated 10/08/2026 |
| Dextrose Monohydrate 50%, Injection, 50% Dextrose Injection 0.5 g/mL; ABBOJECT® Glass Syringe (NDC 0409-4902-34) | Hospira, Inc., a Pfizer Company | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 11/07/2025 Updated 11/07/2025 Discontinued 11/07/2025 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)